LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...

Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation ...

For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the drug's shortage was anything but welcome news. "I had an anxiety attack," said Maria ...

“Price is not a rationale for dispensing a compounded medication, but the fact is, a lot of patients were able to afford the compounded versions of tirzepatide, and they’re likely not going to ...

Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do ...

Tirzepatide acts on GLP-1 plus glucose-dependent insulinotropic ... investors who buy this stock at recent prices could ...

Amid ongoing legal battles over coveted GLP-1 therapies, a drug vendor in Washington state is accused of running an ...

So how does tirzepatide work and differ from Ozempic? And with a price tag of $315–$645 per month for the starting dose, why is it so expensive? Think of tirzepatide as a master key that unlocks ...

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55 ...